Literature DB >> 20599008

Do calcium channel blockers increase the diagnosis of heart failure in patients with hypertension?

Marcelo C Shibata1, Hernando León, Trish Chatterley, Marlene Dorgan, Ben Vandermeer.   

Abstract

Calcium channel blockers (CCBs) are widely used to control hypertension. Previous work suggested that their use could increase heart failure (HF), which is 1 of the consequences of uncontrolled hypertension. Information about the effect of CCBs on incident HF in patients with hypertension is scarce. A systematic review was conducted to evaluate patients with hypertension treated with CCBs and incident HF. An electronic search of publications was conducted using 8 major databases. Studies were eligible if they (1) were randomized clinical trials, (2) performed comparisons of CCBs versus active control, (3) randomized >200 patients, (4) had follow-up periods >6 months, and (5) provided data regarding incident HF. Trials of renal transplantation patients, placebo-controlled trials, and HF trials were excluded. A total of 156,766 patients were randomized to CCBs or control, with a total of 5,049 events. The analysis indicated a significant increase in the diagnosis of HF in patients allocated to CCBs (odds ratio 1.18, 95% confidence interval 1.07 to 1.31). The effect observed was independent of incident myocardial infarction. Subgroup analyses indicated that patients with diabetes were at higher risk for developing HF (odds ratio 1.71, 95% confidence interval 1.21 to 2.41). In conclusion, the results suggest that patients with hypertension treated with CCBs have increased incident HF. Copyright (c) 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20599008     DOI: 10.1016/j.amjcard.2010.02.031

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  4 in total

1.  Associations between relevant cardiovascular pharmacotherapies and incident heart failure in patients with atrial fibrillation: a cohort study in primary care.

Authors:  Per Wändell; Axel C Carlsson; Martin J Holzmann; Johan Ärnlöv; Jan Sundquist; Kristina Sundquist
Journal:  J Hypertens       Date:  2018-09       Impact factor: 4.844

Review 2.  How Heart Rate Should Be Controlled in Patients with Atherosclerosis and Heart Failure.

Authors:  Rose Mary Ferreira Lisboa da Silva; Anaisa Silva Roever Borges; Nilson Penha Silva; Elmiro Santos Resende; Gary Tse; Tong Liu; Leonardo Roever; Giuseppe Biondi-Zoccai
Journal:  Curr Atheroscler Rep       Date:  2018-09-17       Impact factor: 5.113

3.  Use of cardiovascular drugs and risk of incident heart failure in patients with atrial fibrillation.

Authors:  Per Wändell; Axel C Carlsson; Xinjun Li; Martin J Holzmann; Jan Sundquist; Kristina Sundquist
Journal:  J Clin Hypertens (Greenwich)       Date:  2020-07-15       Impact factor: 3.738

4.  RYR3 gene polymorphisms and cardiovascular disease outcomes in the context of antihypertensive treatment.

Authors:  A I Lynch; M R Irvin; E Boerwinkle; B R Davis; L K Vaughan; C E Ford; B Aissani; J H Eckfeldt; D K Arnett; S Shrestha
Journal:  Pharmacogenomics J       Date:  2012-06-05       Impact factor: 3.550

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.